Search explainers, questions, and medicine profiles.
Every published article, newest first. Reporting, explainers, and practical guides on weight and metabolic health.
A short sleep-extension experiment supports a connection with food intake, while leaving long-term weight outcomes uncertain.
Separate semaglutide’s product-specific approvals from the weight-loss and cardiovascular trials that support particular uses.
Retatrutide now has peer-reviewed Phase 3 results, but strong trial findings and routine regulatory approval remain different milestones.
A cardiovascular headline becomes easier to assess when the event counts, baseline risk, and follow-up sit beside the relative effect.
Read the population, comparator, duration, analysis, and harms before deciding what a weight-loss headline really means.
Protein matters, but more is not a universal solution. Pair food planning with activity, function, and an individualized target.
Orforglipron is now FDA-approved as Foundayo for adult weight management; oral delivery does not remove the need for safety review.
A large randomized trial compared supported, quality-focused eating patterns—not every diet carrying a low-carb or low-fat label.
A clear guide to appetite pathways, approved products, trial evidence, and the questions that matter before treatment.
